Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® Laboratory News
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Cipla Limited (BSE: 5
Since it’s an ingredient in so many foods, you h
In a world constantly in motion, Microbioz India r
Mumbai, Baltimore, April 10, 2019: Pharma major Lupin Limited (Lupin) announced the launch of Fluoxetine Tablets USP, 60mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Fluoxetine Tablets USP, 60mg, is the generic version of Alvogen Group Holdings 3 LLC’s Fluoxetine Tablets, 60mg. It is indicated in the treatment of:
Major Depressive Disorder (MDD)
Adults: Efficacy was established in one 5-week trial, three 6-week trials, and one maintenance study
Pediatrics: Efficacy was established in two 8- to 9-week trials of patients 8 to 18 years of age
Obsessive Compulsive Disorder (OCD)
Adults: Efficacy was established in two 13-week trials
Pediatrics: Efficacy was established in one 13-week trial in pediatric patients 7 to 17 years of age
Bulimia Nervosa
Adults: Efficacy was established in two 8-week trials and one 16-week trial
Panic disorder, with or without agoraphobia
Adults: Efficacy was established in two 12-week trials
Fluoxetine Tablets, 60mg, had annual sales of approximately USD 41 million in the US (IQVIA MAT February 2019).
